Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress

Tags:   Stroke  

WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two presentations on sovateltide as a treatment for acute ischemic stroke at the 14th World Stroke Congress October 26-29, 2022, in Singapore.

Details for the presentations are as follows:

About Pharmazz, Inc. 

Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company’s website, www.pharmazz.com.  

---

---

Media contacts:

Katie Larch / Robert Flamm, Ph.D.

Burns McClellan, Inc.

Email: klarch@burnsmc.com / rflamm@burnsmc.com

Investor contacts:

Eric Ando

Burns McClellan, Inc.

Email: eando@burnsmc.com

Shruti Gulati

Pharmazz Inc.

Email: shruti.gulati@pharmazz.com 

Phone: (630) 780-6087